Outlook on the Oligonucleotide Synthesis Global Market - Featuring Abbott Diagnostics, Amyris and Bayer Among Others
03 févr. 2022 04h38 HE
|
Research and Markets
Dublin, Feb. 03, 2022 (GLOBE NEWSWIRE) -- The "Oligonucleotide Synthesis Markets - Forecasts by Oligo Length, Application, and Product - With Executive and Consultant Guides and including Customized...
Genome Editing Market Size ($16.98Bn by 2028) Lead by CRISPR Technology (18.4% CAGR) - Exclusive Research Report by The Insight Partners
20 janv. 2022 12h48 HE
|
The Insight Partners
New York, Jan. 20, 2022 (GLOBE NEWSWIRE) -- According to our new research study on “Genome Editing Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Technology (CRISPR, TALEN,...
Global CRISPR Gene Editing Market Report 2021-2031: Opportunities in Expanding Gene and Cell Therapy Area & CRISPR Gene Editing Scope in Agriculture
14 janv. 2022 05h33 HE
|
Research and Markets
Dublin, Jan. 14, 2022 (GLOBE NEWSWIRE) -- The "CRISPR Gene Editing Market - A Global and Regional Analysis: Focus on Product, Application, End User, and Country-Wise Analysis - Analysis and...
$11.7 Bn Genome Editing/Genome Engineering Markets - Global Analysis & Forecasts to 2026
20 déc. 2021 05h28 HE
|
Research and Markets
Dublin, Dec. 20, 2021 (GLOBE NEWSWIRE) -- The "Genome Editing/Genome Engineering Market - Global Forecast to 2026" report has been added to ResearchAndMarkets.com's offering. The global genome...
Intellia Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of NTLA-2002 for the Treatment of Hereditary Angioedema
13 déc. 2021 07h30 HE
|
Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using...
Intellia Therapeutics Announces Expansion of Ongoing Phase 1 Study of NTLA-2001 to Include Adults with Transthyretin Amyloidosis with Cardiomyopathy (ATTR-CM)
22 nov. 2021 07h30 HE
|
Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA) announced today that the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) has...
Intellia Therapeutics to Highlight Ex Vivo Genome Editing and CRISPR/Cas9 Manufacturing Advances at 2021 American Society of Hematology (ASH) Annual Meeting
05 nov. 2021 07h30 HE
|
Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using...
Global $8.7 Bn Genome Editing Markets to 2026: Focus on CRISPR, TALENs, Zinc Finger Nucleases, Cell Line Engineering, Animal Genetic Engineering
23 sept. 2021 04h08 HE
|
Research and Markets
Dublin, Sept. 23, 2021 (GLOBE NEWSWIRE) -- The "Global Genome Editing Market, By Technique (CRISPR, TALENs, Zinc Finger Nucleases, Others), By Application (Cell Line Engineering, Animal Genetic...
Global CRISPR Markets, 2021-2026 - Rapid Increase in Genetic Disorders to Expand Market Demand
21 sept. 2021 03h48 HE
|
Research and Markets
Dublin, Sept. 21, 2021 (GLOBE NEWSWIRE) -- The "CRISPR Market - Forecasts from 2021 to 2026" report has been added to ResearchAndMarkets.com's offering. The global CRISPR market is evaluated at...
Metagenomic Sequencing Market size worth $ 1,353.28 Million, Globally, by 2028 at 6.35% CAGR: Verified Market Research®
10 août 2021 09h15 HE
|
Verified Market Research
Jersey City, New Jersey, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Verified Market Research recently published a report, “Metagenomic Sequencing Market” By Workflow (Sequencing, Data Processing and...